Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EPS (Weighted Average and Diluted) (2023 - 2025)

NewAmsterdam Pharma's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.63 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 33.68% year-over-year to -$0.63; the TTM value through Dec 2025 reached -$1.72, up 33.33%, while the annual FY2025 figure was -$1.72, 32.81% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.63 at NewAmsterdam Pharma, down from -$0.61 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.14 in Q2 2025 and bottomed at -$1.06 in Q1 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.54 (2023), against an average of -$0.54.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 68.42% in 2024 before it tumbled 238.89% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.6 in 2023, then plummeted by 58.33% to -$0.95 in 2024, then soared by 33.68% to -$0.63 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EPS (Weighted Average and Diluted) are -$0.63 (Q4 2025), -$0.61 (Q3 2025), and -$0.14 (Q2 2025).